Acetyl-L-Carnitine (ALCAR)

Amino Acidoral · inferred

Acetylated form of L-carnitine that crosses the blood-brain barrier. Supports mitochondrial energy production, neuroprotection, and fat metabolism.

Projected serum levels — 500 mg, once daily

Acetyl-L-Carnitine (ALCAR)
Acetyl-L-Carnitine (ALCAR) modeled serum levels, 500 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Acetyl-L-Carnitine (ALCAR) modeled serum levels with a loading dose of 680 mg, then 500 mg once daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 500 mg once daily (oral).

Loading schedule: 680 mg on day 1, then 500 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 54.5 mg, trough ≈ 18.1 mg body load. Population-based estimate over 15 days for a 500 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Amino Acid
Route modeled
Oral
Model confidence
inferred
Half-life
12 h
Common dose
500 mg
Suggested maximum
3k mg/day
Reference dose range
250–3k mg (single dose)
Suggested cadence
once daily

Research behind this entry

  1. Acetyl-L-carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis Veronese N et al. · Psychosomatic Medicine, 2018 DOI

    Meta-analysis of 12 RCTs found acetyl-L-carnitine significantly reduced depressive symptoms compared to placebo, with efficacy comparable to established antidepressants.

  2. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy Sima AA et al. · Diabetes Care, 2005 DOI

    RCT of 1,257 patients found acetyl-L-carnitine (1000 mg three times daily) significantly improved nerve fiber regeneration and reduced pain in diabetic neuropathy.

2 published studies referenced in the app, each with a plain-language summary.